I am honored to release the second part of my two-part interview with Dr. Robert Hariri, CEO of Celularity, Inc.
Celularity is a biotechnology company that specializes in leveraging biologically active cell populations within the postpartum human placenta. Founded on the pioneering work of Dr. Hariri, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth.
In August 2017, Hariri brought Celularity into the spotlight by announcing a successful Series A financing with contributions from influential investors, including Sorrento Therapeutics, United Therapeutics Corporation, and Human Longevity, Inc. (HLI).
On February 15th, 2018, the company broke even bigger news when it announced it had raised $250 million in funding, with contributions from the Genting Group, Tony Robbins, and Dreyfus Family Office, among others.
Celularity has over a dozen pre-clinical trials and Investigational New Drug applications (IND) in progress.
[Read More...]
p.s. Celularity, in collaboration with its strategic partner Sorrento Therapeutics, is developing the world’s first allogeneic off-the-shelf CAR-T cell receptor and CAR-NK products against a number of validated targets for immuno-oncology.
Do you know the identities of the other market competitors developing CAR-T therapies?
|
